Deferiprone, sold under the brand name Ferriprox among others, is a medication that chelates iron and is used to treat iron overload in thalassaemia major. It was first approved and indicated for use in treating thalassaemia major in 1994 and had been licensed for use in the European Union for many years while awaiting approval in Canada and in the United States. On October 14, 2011, it was approved for use in the US under the FDAs accelerated approval program.The most common side effects include red-brown urine (showing that iron is being removed through the urine), nausea (feeling sick), abdominal pain (stomach ache) and vomiting. Less common but more serious side effects are agranulocytosis (very low levels of granulocytes, a type of white blood cell) and neutropenia (low levels of neutrophils, a type of white blood cell that fights infections). Medical uses
Deferiprone monotherapy is indicated in the European Union for the treatment of iron overload in those with thalassaemia major when current chelation therapy is contraindicated or inadequate.Deferiprone in combination with another chelator is indicated in the European Union in those with thalassaemia major when monotherapy with any iron chelator is ineffective, or when prevention or treatment of life-threatening consequences of iron overload (mainly cardiac overload) justifies rapid or intensive correction. Controversy
Deferiprone was at the center of a protracted struggle between Nancy Olivieri, a Canadian haematologist and researcher, and the Hospital for Sick Children and the pharmaceutical company Apotex, that started in 1996, and delayed approval of the drug in North America.
Aluminosis (also known as aluminium lung) is a restrictive lung disease caused by exposure to aluminum-bearing dust. Aluminosis is a form of pneumoconiosis that can lead to pulmonary fibrosis. First cases of lung damage from aluminium exposure were reported in 1930s in Germany. It can be detected by using high-resolution computed tomography. Findings may vary, showing nodular or slightly irregular opacities that may merge into more prominent forms, most frequently in the upper lung fields, sometimes in the lower lung fields, and less frequently a diffuse micro nodular pattern. In severe cases, pulmonary fibrosis with honeycombing was described.Workers exposed to aluminium dust are often involved in industries such as explosives manufacturing (where aluminium powder is involved), aluminium welding (and grinding), and bauxite smelting. References
External links

https://icdlist.com/icd-10/J63.0